Donate Now
PI(s): Vanessa Dalton, Lisa Harris
Target specific oral anticoagulants (TSOAC)s including dabigatran, rivaroxaban, and apixaban represent novel alternatives to vitamin K antagonists.
PI(s): Reshma Jagsi
Co-I(s): Sarah Hawley